Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
Open accessAbstract
Background & aims There have been few studies of the role of de novo lipogenesis in the development of nonalcoholic fatty liver disease (NAFLD). We used isotope analyses to compare de novo lipogenesis and fatty acid flux between subjects with NAFLD and those without, matched for metabolic factors (controls).Methods We studied subjects with metabolic syndrome and/or levels of alanine aminotransferase and aspartate aminotransferase >30 mU/L, using magnetic resonance spectroscopy to identify those with high levels (HighLF, n = 13) or low levels (LowLF, n = 11) of liver fat. Clinical and demographic information was collected from all participants, and insulin sensitivity was measured using the insulin-modified intravenous glucose tolerance test. Stable isotopes were administered and gas chromatography with mass spectrometry was used to analyze free (nonesterified) fatty acid (FFA) and triacylglycerol flux and lipogenesis.Results Subjects with HighLF (18.4% ± 3.6%) had higher plasma levels of FFAs during the nighttime and higher concentrations of insulin than subjects with LowLF (3.1% ± 2.7%; P = .04 and P < .001, respectively). No differences were observed between groups in adipose flux of FFAs (414 ± 195 μmol/min for HighLF vs 358 ± 105 μmol/min for LowLF; P = .41) or production of very-low-density lipoprotein triacylglycerol from FFAs (4.06 ± 2.57 μmol/min vs 4.34 ± 1.82 μmol/min; P = .77). In contrast, subjects with HighLF had more than 3-fold higher rates of de novo fatty acid synthesis than subjects with LowLF (2.57 ± 1.53 μmol/min vs 0.78 ± 0.42 μmol/min; P = .001). As a percentage of triacylglycerol palmitate, de novo lipogenesis was 2-fold higher in subjects with HighLF (23.2% ± 7.9% vs 10.1% ± 6.7%; P < .001); this level was independently associated with the level of intrahepatic triacylglycerol (r = 0.53; P = .007).Conclusions By administering isotopes to subjects with NAFLD and control subjects, we confirmed that those with NAFLD have increased synthesis of fatty acids. Subjects with NAFLD also had higher nocturnal plasma levels of FFAs and did not suppress the contribution from de novo lipogenesis on fasting. These findings indicate that lipogenesis might be a therapeutic target for NAFLD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fasting DNL correlated with plasma TAG concentrations and was higher in individuals with MASLD.
“Fasting DNL correlated with plasma TAG concentrations48 and was higher in individuals with MASLD.49”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [49]
Postprandial DNL contributes to 15-26% of liver TAGs in individuals with MASLD vs. 1-6% in the fasting state in healthy individuals.
“Postprandial DNL contributes to 15-26% of liver TAGs in individuals with MASLD49,56 vs. 1-6% in the fasting state in healthy individuals.48”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · see citing works
Self-citationDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · see citing works
Self-citationNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · see citing works
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · see citing works
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · see citing works
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765 · see citing works
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435 · see citing works
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107 · see citing works
Charlton, M., Burns, J. M., Pedersen, R. A., Watt, K. D. S., Heimbach, J. K., & Dierkhising, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.061 · Cited by 1,103 · see citing works
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816 · see citing works
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759 · see citing works
Wei, Y., Wang, D., Topczewski, F., & Pagliassotti, M. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00644.2005 · Cited by 736 · see citing works
Li, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733 · cited 1× · see citing works
“Indeed, in rodent studies, hepatic insulin resistance is characterized by a bifurcation of insulin signaling in which glucose production is resistant to the inhibitory effects of insulin but lipogenesis is not and is, in fact, stimulated.(50) Mounting data have supported the concept that stimulation of lipogenesis can…”
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672 · see citing works
Self-citationFabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631 · see citing works
Korenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592 · see citing works
Schwarz, J.-M., Linfoot, P., Dare, D., & Aghajanian, K. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.43 · Cited by 496 · see citing works
Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 461 · see citing works
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440 · see citing works
Diraison, F., Moulin, P., & Beylot, M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70061-7 · Cited by 435 · see citing works
Diagnosis and management of the metabolic syndrome
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 434 · see citing works
Mechanisms for the acute effect of fructose on postprandial lipemia
Chong, M. F., Fielding, B. A., & Frayn, K. N. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.6.1511 · Cited by 367 · see citing works
Parks, E. J., Krauss, R. M., Christiansen, M. P., Neese, R. A., & Hellerstein, M. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6572 · Cited by 350 · see citing works
Self-citationDietary Sugars Stimulate Fatty Acid Synthesis in Adults3
Parks, E. J., Skokan, L. E., Timlin, M. T., & Dingfelder, C. S. (2008) · Journal of Nutrition · doi:10.1093/jn/138.6.1039 · Cited by 315 · see citing works
Self-citationHaufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307 · see citing works
The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects
Chen, X., Iqbal, N., & Boden, G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5479 · Cited by 291 · see citing works
Barrows, B. R., & Parks, E. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1709 · Cited by 273 · see citing works
Self-citationSchneeman, B. O., Kotite, L., Todd, K., & Havel, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2069 · Cited by 255 · see citing works
Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V., Hardies, J., & Cusi, K. J. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253 · see citing works
De novo lipogenesis in humans: metabolic and regulatory aspects
Hellerstein, M. (1999) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600744 · Cited by 246 · see citing works
Schwarz, J., Neese, R. A., Turner, S., Dare, D., & Hellerstein, M. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118342 · Cited by 244 · see citing works
Hudgins, L. C., Hellerstein, M. K., Seidman, C. E., Neese, R. A., Tremaroli, J. D., & Hirsch, J. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32407-x · Cited by 216 · see citing works
Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., Peltonen, M., Romeo, S., Lundbom, J., Lundbom, N., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038695 · Cited by 211 · cited 1× · see citing works
“Further, of the numerous investigations showing elevated adipose free fatty acid (FFA) flux as a prominent feature in NAFLD, a role for lipogenesis has been implicated indirectly.(30) In an elegant study by Fabbrini et al, after labeling the plasma FFA pool into VLDL-TG, a high percentage of TGFA remained unlabeled(7)…”
Temporal pattern of de novo lipogenesis in the postprandial state in healthy men1–3
Timlin, M. T., & Parks, E. J. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.35 · Cited by 170 · see citing works
Self-citationMarques-Lopes, I., Ansorena, D., Astiasarán, I., Forga, L., & Martínez, J. A. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.253 · Cited by 159 · see citing works
Peter, A., Čegan, A., Wagner, S., Lehmann, R., Stefan, N., Königsrainer, A., Königsrainer, I., Häring, H., & Schleicher, E. D. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.127274 · Cited by 130 · see citing works
Turner, S., Murphy, E. J., Neese, R. A., Antelo, F., Thomas, T. A., Agarwal, A., Go, C., & Hellerstein, M. K. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00402.2002 · Cited by 127 · see citing works
Human fatty acid synthesis is reduced after the substitution of dietary starch for sugar
Hudgins, L., Seidman, C. E., Diakun, J., & Hirsch, J. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.4.631 · Cited by 123 · see citing works
Ravikumar, B., Carey, P. E., Snaar, J. E. M., Deelchand, D. K., Cook, D. B., Neely, R. D. G., English, P. T., Firbank, M., Morris, P. G., & Taylor, R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00557.2004 · Cited by 122 · see citing works
Vedala, A., Wang, W., Neese, R. A., Christiansen, M. P., & Hellerstein, M. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600200-jlr200 · Cited by 117 · see citing works
Ins and Outs Modulating Hepatic Triglyceride and Development of Nonalcoholic Fatty Liver Disease
Goldberg, I. J., & Ginsberg, H. N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.040 · Cited by 99 · see citing works
Reduced oxidation of dietary fat after a short term high-carbohydrate diet
Roberts, R., Bickerton, A. S. T., Fielding, B. A., Blaak, E. E., Wagenmakers, A. J. M., Chong, M. F., Gilbert, M., Karpe, F., & Frayn, K. N. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.4.824 · Cited by 92 · see citing works
Postprandial Lipemia Associates with Liver Fat Content
Matikainen, N., Mänttäri, S., Westerbacka, J., Vehkavaara, S., Lundbom, N. M. I., Yki‐Järvinen, H., & Taskinen, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0187 · Cited by 76 · see citing works
Manchanayake, J., Chitturi, S., Nolan, C. J., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06528.x · Cited by 71 · see citing works
Increased Dietary Substrate Delivery Alters Hepatic Fatty Acid Recycling in Healthy Men
Timlin, M. T., Barrows, B. R., & Parks, E. J. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2694 · Cited by 67 · see citing works
Self-citationWilke, M. S., French, M. A., Goh, Y. K., Ryan, E. A., Jones, P. J. H., & Clandinin, M. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1405-9 · Cited by 62 · see citing works
Validity of the Actical for estimating free-living physical activity
Crouter, S. E., DellaValle, D. M., Horton, M., Haas, J. D., Frongillo, E. A., & Bassett, D. R. (2010) · European Journal of Applied Physiology · doi:10.1007/s00421-010-1758-2 · Cited by 59 · see citing works
VLDL-triglyceride production after alcohol ingestion, studied using [2-13C1] glycerol
Siler, S. Q., Neese, R. A., Parks, E. J., & Hellerstein, M. K. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33311-3 · Cited by 59 · see citing works
Self-citationStable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism1,2
Murphy, E. J. (2006) · Journal of Animal Science · doi:10.2527/2006.8413_supple94x · Cited by 56 · see citing works
Use of stable isotopically labeled tracers for studies of metabolic kinetics: An overview
Patterson, B. W. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90260-2 · Cited by 54 · see citing works
Defective Liver Disposal of Free Fatty Acids in Patients with Impaired Glucose Tolerance
Iozzo, P., Turpeinen, A., Takala, T., Oikonen, V., Bergman, J. R., Grönroos, T. J., Ferrannini, E., Nuutila, P., & Knuuti, J. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031142 · Cited by 45 · see citing works
Nonalcoholic fatty liver disease (NAFLD): Is it really a serious condition?
Wattacheril, J. J., & Chalasani, N. (2012) · Hepatology · doi:10.1002/hep.26031 · Cited by 37 · see citing works
Mager, D. R., Mazurak, V. C., Rodriguez‐Dimitrescu, C., Vine, D. F., Jetha, M. M., Ball, G. D. C., & Yap, J. Y. K. (2012) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607112467820 · Cited by 34 · see citing works
Insulin Activation of Plasma Nonesterified Fatty Acid Uptake in Metabolic Syndrome
Ramos-Román, M. A., Lapidot, S. A., Phair, R. D., & Parks, E. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.250019 · Cited by 32 · see citing works
Self-citationSystemic Free Fatty Acid Disposal Into Very Low-Density Lipoprotein Triglycerides
Koutsari, C., Mundi, M. S., Ali, A. H., Patterson, B. W., & Jensen, M. D. (2013) · Diabetes · doi:10.2337/db12-1557 · Cited by 21 · see citing works
PNPLeAse Get the Fats Right: Does Lipogenesis or Lipolysis Cause NASH?1,‡
Farrell, G. C. (2010) · Hepatology · doi:10.1002/hep.23867 · Cited by 16 · see citing works
Glass, L. C., Cusi, K. J., Berria, R., Petz, R., Cersósimo, E., DeFronzo, R. A., & Gastaldelli, A. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03811.x · Cited by 15 · see citing works
Effect of Insulin Infusion on Spillover of Meal-Derived Fatty Acids
Muthusamy, K., Nelson, R. H., Singh, E., Vlazny, D. T., Smailovic, A., & Miles, J. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1468 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119 · see citing works
“levels of FFAs [25].”
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · see citing works
Jung, U. J., & Choi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,898 · see citing works
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471 · see citing works
“7%, n = 11) while being matched for adiposity and circulating lipids [39].”
BackgroundNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,260 · see citing works
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · see citing works
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002 · see citing works
Nonalcoholic fatty liver disease
Brunt, E., Wong, V., Nobili, V., Day, C., Sookoian, S., Maher, J., Bugianesi, E., Sirlin, C., Neuschwander-Tetri, B., & Rinella, M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 591 · see citing works
Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications
Carta, G., Murru, E., Banni, S., & Manca, C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00902 · Cited by 813 · see citing works
“In an experiment where isolated rat hepatocytes were subjected to oxidative stress, Giron-Calle et al. (Giron-Calle et al., 1997) demonstrated that TAG could serve as an expendable FA reserve, providing a limited but very dynamic pool of PUFA for the resynthesis of PL (Giron-Calle et al., 1997).”
BackgroundInfluentialInsulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · see citing works
“Studies using this approach reported that DNL accounts for 15% to 26% of IHTGpalmitate production in people with NAFLD (12, 14-16) and 1% to 10% of IHTG-palmitate production in people who are either lean or obese with normal IHTG content (14, 17-20).”
BackgroundMethodResultInfluentialRole of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709 · see citing works
AMPK as a Therapeutic Target for Treating Metabolic Diseases
Day, E. A., Ford, R. J., & Steinberg, G. R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.004 · Cited by 620 · see citing works
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · see citing works
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553 · see citing works
A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593 · see citing works
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 558 · see citing works
“Importantly, the molar ratio of VLDL-TG (particle TG content) to VLDL-ApoB100 (the number of particles) is elevated in nondiabetic obese individuals with high intrahepatic TG (measured by MRS), suggesting that the secreted VLDL particles are larger and resemble the pro-atherogenic VLDL1 [65].”
BackgroundInfluentialArroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. J. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 531 · see citing works
“This is due to an increased FFA uptake from dietary sources, increased de novo lipogenesis [59], and enhanced lipolysis in adipose tissue, which increases FFA delivery to the liver [60,61].”
BackgroundEmerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 507 · see citing works
Treatment of nonalcoholic fatty liver disease: role of AMPK
Smith, B. K., Marcinko, K., Desjardins, E. M., Lally, J., Ford, R. J., & Steinberg, G. R. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00225.2016 · Cited by 502 · see citing works
“This depression in DNL with a HFD is in direct contrast to the human condition, whereby DNL rates are elevated fivefold (17, 62).”
BackgroundResultLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461 · see citing works
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · see citing works
“9%) [6,7], we still observed a significant reduction in the percentage of hepatic DNL with liraglutide vs.”
BackgroundResultFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455 · see citing works
Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.003 · Cited by 450 · see citing works
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440 · see citing works
“Recently the significant contribution of DNL to fat in hepatocytes in NAFLD has been demonstrated in humans [114].”
BackgroundRole of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448 · see citing works
“In an experiment conducted with isotopes, a threefold increase of DNL and higher nocturnal plasma levels of FFAs were observed in patients with NAFLD [41].”
BackgroundLuukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428 · see citing works
“Respiratory gas exchange and rates of resting energy expenditure and substrate oxidation were recorded by indirect calorimetry as described (14).”
MethodUnraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 437 · see citing works
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419 · see citing works
“…it has been established that humans with NAFLD have significantly higher rates of hepatic DNL compared to lean individuals (Donnelly et al., 2005; Fabbrini et al., 2008; Lambert et al., 2014); thus it is possible that inhibiting DNL might reduce hepatic steatosis in humans as it did in rodents.”
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 420 · see citing works
“Recent evidence indicates that immunologic imbalances in the liver support the maintenance and progression of inflammation in NAFLD.”
BackgroundInfluentialCurrent and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2016) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410 · see citing works
“8 9 In addition, de novo lipogenesis is increased, 10 driven by the hyperinsulinemia as well as excess availability of carbohydrates.”
BackgroundmTORC2 Promotes Tumorigenesis via Lipid Synthesis
Guri, Y., Colombi, M., Dazert, E., Hindupur, S. K., Roszik, J., Moes, S., Jenoe, P., Heim, M. H., Riezman, I., Riezman, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.011 · Cited by 410 · see citing works
Stefan, N., Yki‐Järvinen, H., & Neuschwander‐Tetri, B. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 414 · see citing works
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
Satapati, S., Kucejová, B., Duarte, J. A. G., Fletcher, J. A., Reynolds, L., Sunny, N. E., He, T., Nair, L. A., Livingston, K. A., Fu, X., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82204 · Cited by 400 · see citing works
Self-citationPathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease.
Haas, J., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 372 · see citing works
Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01425-3 · Cited by 368 · see citing works
Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
ter Horst, K. W., & Serlie, M. J. M. (2017) · Nutrients · doi:10.3390/nu9090981 · Cited by 365 · see citing works
“In contrast, DNL was 3-fold greater in NAFLD compared to the control subjects [19], suggesting that increased DNL is a distinct pathophysiological feature of human NAFLD.”
BackgroundInfluentialEffect of ethanol on lipid metabolism
You, M., & Arteel, G. E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.037 · Cited by 357 · see citing works
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Softic, S., Gupta, M. K., Wang, G.-X., Fujisaka, S., O'Neill, B. T., Rao, T. N., Willoughby, J. L. S., Harbison, C. E., Fitzgerald, K. J., Ilkayeva, O., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94585 · Cited by 349 · see citing works
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333 · see citing works
“One metabolic process thought to initiate NAFLD is de novo lipogenesis (DNL), whose rate is up to 3-fold higher in NAFLD patients (Lambert et al., 2014).”
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · see citing works
Resolving the paradox of hepatic insulin resistance
Santoleri, D., & Titchenell, P. M. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.016 · Cited by 336 · see citing works
“Isotope labeling experiments in subjects with NAFLD showed that subjects with increased hepatic steatosis had 2fold higher rates of de novo lipogenesis and increased plasma levels of free fatty acids (FFAs) and insulin.(8) In addition to increased lipid synthesis, insulin-resistant individuals have increased rates of…”
BackgroundNonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330 · see citing works
“independently associated with hepatic TAG in individuals with NAFLD [102].”
BackgroundPathogenesis and Prevention of Hepatic Steatosis.
Nassir, F., Rector, R. S., Hammoud, G. M., & Ibdah, J. A. (2015) · PubMed Central · Cited by 321 · see citing works
Sunny, N. E., Bril, F., & Cusi, K. J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.006 · Cited by 322 · see citing works
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 313 · see citing works
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 311 · see citing works
Acetyl-CoA metabolism in cancer
Guertin, D. A., & Wellen, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00543-5 · Cited by 303 · see citing works
Nonalcoholic fatty liver disease and aging: Epidemiology to management
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 309 · see citing works
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Argüello, G., Balboa, E., Arrese, M. A., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306 · see citing works
High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms
Lian, C.-Y., Zhai, Z., Li, Z., & Wang, L. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109199 · Cited by 304 · see citing works
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 332 · see citing works
“Lipolysis in peripheral adipose tissue or dietary sugars or amino acids that are converted to saturated fatty acids via hepatic de novo lipogenesis contributes to the formation of intrahepatic triglycerides 80,81 .”
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 298 · see citing works
Trépo, E., Romeo, S., Zucman‐Rossi, J., & Nahon, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.011 · Cited by 293 · see citing works
Quantitative Fluxomics of Circulating Metabolites
Hui, S. T., Cowan, A. J., Zeng, X., Yang, L., TeSlaa, T. A., Li, X., Bartman, C., Zhang, Z., Jang, C., Wang, L., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.013 · Cited by 274 · see citing works
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294 · see citing works
Gastrointestinal Complications of Obesity
Camilleri, M., Malhi, H., & Acosta, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.052 · Cited by 269 · see citing works
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 272 · see citing works
“Besides the increased uptake of NEFAs in early NAFLD, de novo lipogenesis in response to high-carbohydrate feeding leads to the accumulation of TAGs within the liver (108).”
Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276 · see citing works
Schwarz, J., Noworolski, S. M., Erkin‐Cakmak, A., Korn, N. J., Wen, M., Tai, V., Jones, G. M., Palii, S. P., Velasco-Alin, M., Pan, K. D. H., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.043 · Cited by 272 · see citing works
“However, increased DNL has been demonstrated in adults with NAFLD.(35) Using stable isotopes, Donnelly et al.”
BackgroundInfluentialEffect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys
Schwimmer, J. B., Ugalde‐Nicalo, P., Welsh, J. A., Angeles, J. E., Cordero, M., Adams, K. H., Alazraki, A. L., Durelle, J., Knight‐Scott, J., Newton, K. P., et al. (2019) · JAMA · doi:10.1001/jama.2018.20579 · Cited by 266 · see citing works
Luukkonen, P. K., Dufour, S., Lyu, K., Zhang, X., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki‐Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 253 · see citing works
Geidl-Flueck, B., Hochuli, M., Németh, Á., Eberl, A., Derron, N., Köfeler, H. C., Tappy, L., Berneis, K., Spinas, G. A., & Gerber, P. A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.027 · Cited by 238 · see citing works
“Nevertheless, our data demonstrates that fructose consumed in SSBs is a potent stimulator of de novo lipogenesis which is recognized per se as a risk factor for NAFLD and diabetes.(40,41) Increased hepatic lipogenic activity and concurrently increased intestinal fructose absorption and hepatic clearance capacity may i…”
BackgroundHendriks, D. F. G., Brouwers, J. F. H. M., Hamer, K. M., Geurts, M. H., Luciana, L., Massalini, S., López‐Iglesias, C., Peters, P. J., Colman, M. J. R., Lopes, S. M. C. D. S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01680-4 · Cited by 251 · see citing works
“Clinical studies have indeed reported increased rates of DNL as a distinct feature of NAFLD patients 52 , making it a potential, clinically attractive mechanism to combat steatosis.”
BackgroundPhysiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 248 · see citing works
Cefalu, W. T., Bray, G. A., Home, P., Garvey, W. T., Klein, S., Pi-Sunyer, X., Hu, F. B., Raz, I., Gaal, L. V., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 245 · see citing works
“People with NAFLD also have an increase in hepatic de novo lipogenesis (44) and in VLDL-triglyceride secretion rate compared with people with obesity and normal IHTG content (45).”
BackgroundThe circadian clock and liver function in health and disease
Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.020 · Cited by 246 · see citing works
“Increased FFA release from adipocytes due to insulin resistance (51) and conversion of excess carbohydrates to FFA via hepatic de novo lipogenesis (DNL) (52) are two major sources of TG deposition during NAFLD development, in addition to excess caloric intake.”
BackgroundBates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230 · see citing works
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235 · see citing works
Therapies in non‐alcoholic steatohepatitis ( NASH )
Oseini, A. M., & Sanyal, A. J. (2017) · Liver International · doi:10.1111/liv.13302 · Cited by 235 · see citing works
Harjumäki, R., Pridgeon, C. S., & Ingelman‐Sundberg, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158221 · Cited by 237 · see citing works
“De novo lipogenesis and fatty acid oxidation are implicated in NAFLD pathogenesis, although lipid uptake, storage and export also play a role [126,127].”
BackgroundNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228 · see citing works
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225 · see citing works
“In addition to adipose-tissue-derived FFAs, increased dietary fat and carbohydrate uptake (especially fructose) can also contribute to steatosis in the liver (Faeh et al., 2005; Lomonaco et al., 2012; Lambert et al., 2014).”
BackgroundInfluentialMetabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 223 · see citing works
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219 · see citing works
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222 · see citing works
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240 · see citing works
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217 · see citing works
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 209 · see citing works
“Maximal reduction of liver fat appears to require both inhibition of hepatic de novo lipogenesis and suppression of adipose tissue lipolysis (51, 52).”
BackgroundCD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing
Zeng, H., Qin, H., Liao, M., Zheng, E., Luo, X., Xiao, A., Li, Y., Chen, L., Wei, L., Zhao, L., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101428 · Cited by 211 · see citing works
“Human isotope-labeling studies demonstrated a threefold increase of DNL contributed to hepatic TG accumulation in patients with NAFLD than those without [5].”
BackgroundLipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
Hall, Z., Bond, N. J., Ashmore, T., Sanders, F., Ament, Z., Wang, X., Murray, A. J., Bellafante, E., Virtue, S., Vidal‐Puig, A., et al. (2016) · Hepatology · doi:10.1002/hep.28953 · Cited by 211 · see citing works
“Overall, we detected 34 different eicosanoids and lipid mediators including AAderived hydroxyeicosatetranoic acids (HETEs, 6), epoxyeicosatrienoic acids (EETs, 2), dihydroxyeicosatrienoic acids (DHETs, 3), prostaglandins (6); linoleic acid (LA)-derived hydroxyoctadecadienoic acids (HODEs, 2), epoxyoctadecaneoic acids…”
BackgroundIntestinal microbiome and NAFLD: molecular insights and therapeutic perspectives
Hu, H., Lin, A., Kong, M., Yao, X., Yin, M., Xia, H., Ma, J., & Liu, H. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01649-8 · Cited by 208 · see citing works
Ziółkowska, S., Binienda, A., Jabłkowski, M., Szemraj, J., & Czarny, P. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011128 · Cited by 209 · see citing works
“Additionally, patients with NAFLD have a higher synthesis of fatty acids as compared to healthy controls [33].”
BackgroundNon-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 209 · see citing works
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 205 · see citing works
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207 · see citing works
“accumulation 86,87 .”
Yu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199 · see citing works
“The role of DNL in the development of hepatic steatosis is further supported by a recent study in subjects withmetabolic syndrome and a high content of liver fat [24].”
BackgroundBiomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease
Mato, J. M., Alonso, C., Noureddin, M., & Lu, S. C.-L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.3009 · Cited by 201 · see citing works
De novo lipogenesis in metabolic homeostasis: More friend than foe?
Solinas, G., Borén, J., & Dulloo, A. G. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.004 · Cited by 197 · see citing works
“A more recent study from the same laboratory investigated the contribution of the different lipid sources above to liver fat of human subjects with either low or high liver lipid content but with similar adiposity [11].”
BackgroundInfluentialInhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199 · see citing works
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Ferrara, D., Montecucco, F., Dallegri, F., & Carbone, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28821 · Cited by 195 · see citing works
Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver
Fletcher, J. A., Deja, S., Satapati, S., Fu, X., Burgess, S. C., & Browning, J. D. (2019) · JCI Insight · doi:10.1172/jci.insight.127737 · Cited by 195 · see citing works
“This may be clinically relevant, given that impaired ketogenesis in rodents is sufficient to exacerbate steatosis, stimulate the TCA cycle, increase gluconeogenesis and DNL, and promote liver injury — all characteristic features of NAFLD and NASH (23, 24).”
BackgroundSelf-citationHepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191 · see citing works
“Interestingly, dietary fructose more robustly induces DNL in patients with fatty liver disease (Lambert et al. 2014).”
BackgroundParlati, L., Régnier, M., Guillou, H., & Postic, C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100346 · Cited by 190 · see citing works
Ins and outs of the TCA cycle: the central role of anaplerosis
Inigo, M., Deja, S., & Burgess, S. C. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120420-025558 · Cited by 189 · see citing works
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 192 · see citing works
“It has been suggested that an abnormally high DNL could potentially contribute to the development of MAFLD [36].”
BackgroundPathophysiology of lipid droplet proteins in liver diseases
Carr, R. M., & Ahima, R. S. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.10.021 · Cited by 180 · see citing works
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F. M., & Mehal, W. Z. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 179 · see citing works
“Patients with MASLD were found to have higher basal and nocturnal FFA levels and did not suppress DNL upon fasting 36 .”
Laursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.138 · Cited by 176 · see citing works
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Ramanathan, R., Ali, A. H., & Ibdah, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137280 · Cited by 179 · see citing works
“It has been shown that patients with NAFLD may have abnormally high levels of hepatic DNL [46].”
BackgroundHarrison, S. A., Rolph, T., Knott, M., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.034 · Cited by 176 · see citing works
- Authors
- Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Parks, Elizabeth J.
- ORCID
- Parks, Elizabeth J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 146
- Issue
- 3
- Pages
- 726-735
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC6276362
- OpenAlex
- W2139351004
- Cited by
- 1,069
- References
- 58
- Citations by year
- 2026: 67 · 2025: 111 · 2024: 110 · 2023: 108 · 2022: 124 · 2021: 111 · 2020: 106 · 2019: 92 · 2018: 75 · 2017: 47 · 2016: 49 · 2015: 45 · 2014: 23
- FWCI
- 28.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (RL1DK081187, UL1DE019584, UL1-RR024982)
- National Center for Advancing Translational Sciences (RL1DK081187, UL1DE019584, UL1-RR024982)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- de novo lipogenesis, non-alcoholic fatty liver disease, fatty acid synthesis, triglyceride synthesis, liver fat, metabolic syndrome, insulin sensitivity, stable isotope tracer studies, hepatic lipid metabolism, insulin
- MeSH terms
- Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Hyperlipidemias, Liver, Magnetic Resonance Imaging, Male, Comorbidity, Case-Control Studies, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
